Maneesh Jain

Adela, Inc. is a company that is developing technology to accelerate the diagnosis and improve the management of cancer through blood tests for minimal residual disease (MRD) monitoring and multi-cancer early detection (MCED). The company is based in Branford, CT. The company's genome-wide methylome enrichment platform captures extensive, biologically-relevant genomic information to maximize test performance and improve treatment decisions. Adela's approach to MRD testing is tissue agnostic, eliminating the burden of acquiring a tumor sample. The CEO of the company is Scott Bratman.

Adela, Inc. is a company that is developing technology to accelerate the diagnosis and improve the management of cancer through blood tests for minimal residual disease (MRD) monitoring and multi-cancer early detection (MCED). The company is based in Branford, CT. The company's genome-wide methylome enrichment platform captures extensive, biologically-relevant genomic information to maximize test performance and improve treatment decisions. Adela's approach to MRD testing is tissue agnostic, eliminating the burden of acquiring a tumor sample. The CEO of the company is Scott Bratman.

Adela, Inc. is a company that is developing technology to accelerate the diagnosis and improve the management of cancer through blood tests for minimal residual disease (MRD) monitoring and multi-cancer early detection (MCED). The company is based in Branford, CT. The company's genome-wide methylome enrichment platform captures extensive, biologically-relevant genomic information to maximize test performance and improve treatment decisions. Adela's approach to MRD testing is tissue agnostic, eliminating the burden of acquiring a tumor sample. The CEO of the company is Scott Bratman.

Adela, Inc. is a company that is developing technology to accelerate the diagnosis and improve the management of cancer through blood tests for minimal residual disease (MRD) monitoring and multi-cancer early detection (MCED). The company is based in Branford, CT. The company's genome-wide methylome enrichment platform captures extensive, biologically-relevant genomic information to maximize test performance and improve treatment decisions. Adela's approach to MRD testing is tissue agnostic, eliminating the burden of acquiring a tumor sample. The CEO of the company is Scott Bratman.

Adela, Inc. is a company that is developing technology to accelerate the diagnosis and improve the management of cancer through blood tests for minimal residual disease (MRD) monitoring and multi-cancer early detection (MCED). The company is based in Branford, CT. The company's genome-wide methylome enrichment platform captures extensive, biologically-relevant genomic information to maximize test performance and improve treatment decisions. Adela's approach to MRD testing is tissue agnostic, eliminating the burden of acquiring a tumor sample. The CEO of the company is Scott Bratman.